Cancer Immunology: Bench to Bedside Immunotherapy of Cancers
Editat de Nima Rezaeien Limba Engleză Paperback – 5 oct 2016
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (5) | 871.16 lei 38-44 zile | |
| Springer Berlin, Heidelberg – 22 aug 2016 | 1308.15 lei 3-5 săpt. | |
| Springer Berlin, Heidelberg – 5 oct 2016 | 871.16 lei 38-44 zile | |
| Springer International Publishing – 14 dec 2021 | 967.22 lei 38-44 zile | |
| Springer International Publishing – 27 sep 2021 | 976.34 lei 38-44 zile | |
| Springer International Publishing – 25 aug 2021 | 1001.67 lei 38-44 zile | |
| Hardback (2) | 1345.86 lei 38-44 zile | |
| Springer International Publishing – 13 dec 2020 | 1345.86 lei 38-44 zile | |
| Springer International Publishing – 29 ian 2020 | 1389.23 lei 38-44 zile |
Preț: 871.16 lei
Preț vechi: 917.02 lei
-5% Nou
Puncte Express: 1307
Preț estimativ în valută:
166.80€ • 171.10$ • 140.43£
166.80€ • 171.10$ • 140.43£
Carte tipărită la comandă
Livrare economică 22-28 februarie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783662513835
ISBN-10: 3662513838
Pagini: 535
Ilustrații: L, 485 p. 45 illus., 38 illus. in color.
Dimensiuni: 178 x 254 x 30 mm
Greutate: 0 kg
Ediția:Softcover reprint of the original 1st ed. 2015
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
ISBN-10: 3662513838
Pagini: 535
Ilustrații: L, 485 p. 45 illus., 38 illus. in color.
Dimensiuni: 178 x 254 x 30 mm
Greutate: 0 kg
Ediția:Softcover reprint of the original 1st ed. 2015
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
Cuprins
Frontiers in Cancer Immunotherapy.- Novel Strategy of Cancer Immunotherapy: Spiraling Up.- Novel Prognostic Biomarkers for Personalized Cancer Treatments.- Tumor Antigen and Epitope Identification for Pre-Clinical and Clinical Evaluation.- Strategies to Target Tumor Immunesuppression.- Immune Modulation of Drugs in Prevention and Treatment of Cancers.- Overcoming Immune Tolerance With Immune Checkpoint Blockade.- Gene therapy and Virus-Based Cancer Vaccines.- Cancer Stem Cells: Biology and Potential therapeutic Applications.- Hematopoietic Stem Cell Transplantation and Lymphodepletion in Treatment of Cancers.- Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers.- T Cell Immunotherapy: From Synthetic Biology to Clinical Practice.- Role of Gamma-Delta T Lymphocytes in Cancer Immunosurveillance and Immunotherapy.- Adoptive T Cell therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotherapy.- Cellular therapy of Cancer With B Effector Cells.- Monoclonal Antibodies for Treatment of Cancers.- Pattern Recognition Receptors in Cancers and Immunotherapy by Triggering or Targeting of Toll Like Receptors Pathway.- Recent Advances in the Use of NK Cells Against Cancer.- Dendritic Cell Vaccines for Cancer Therapy: Fundamentals and Clinical Trials.- Tumor Associated Macrophages and iNOS in Cancer Immunotherapy.- Photodynamic therapy and Anti-Tumor Immune Response.- Polarization of Tumor Milieu: Therapeutic Implications.- Immunotherapies Targeting 5T4 Oncofoetal Glycoprotein.- Immune Monitoring During Clinical Development of Anti-CTLA-4 Antibody Therapy.- PD-1 Blockade in Cancer Therapy.- New Advances in Radioimmunotherapy for the Treatment of Cancers.- Psychoneuroendocrinoimmunotherapy of Cancers.- Ethical Considerations in Cancer Immunotherapy.
Notă biografică
Nima Rezaei gained his medical degree from Tehran University of Medical Sciences and Health Services in 2002 and subsequently obtained MSc in Molecular and Genetic Medicine and PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Since 2010, Dr. Rezaei has worked at the Department of Immunology, School of Medicine, Tehran University of Medical Sciences; he is also the Chief Executive Director of the Children’s Medical Center Hospital, Tehran and a co-founder and Deputy President of the Research Center for Immunodeficiencies. In addition, Dr. Rezaei is an Honorary Research Fellow at the Department of Infection and Immunity, School of Medicine and Biomedical Sciences, University of Sheffield. Dr. Rezaei has already been the Director of more than 50 research projects and has designed and participated in several international collaborative projects. Dr. Rezaei is an editorial assistant or board member for more than 20 international journals. He has published more than 400 articles in international scientific journals and edited ten further books.
Textul de pe ultima copertă
This translational book describes in detail the clinical application of novel approaches in cancer immunotherapy with the aim of educating clinicians in the implications of the most recent research and new developments in the field. The scope is broad, encompassing, for example, prognostic biomarkers for personalized cancer treatment, strategies for targeting tumor immunosuppression, gene therapy, virus-based vaccines, targeting of cancer stem cells, hematopoietic stem cell transplantation, the role of T lymphocytes in cancer immunotherapy, use of monoclonal antibodies, and many more innovative approaches. Clinical immunologists, hematologists, and oncologists in particular will find the book to be of value in expanding their knowledge.
The book is the second in a three-volume series, Cancer Immunology, which offers an up-to-date review of cancer immunology and immunotherapy. The remaining volumes focus on the immunopathology of cancers and cancer immunotherapy for organ-specific tumors. In total the series, designed for both clinicians and researchers, includes contributions from more than 250 scientists working at leading universities and institutes from across the world.
The book is the second in a three-volume series, Cancer Immunology, which offers an up-to-date review of cancer immunology and immunotherapy. The remaining volumes focus on the immunopathology of cancers and cancer immunotherapy for organ-specific tumors. In total the series, designed for both clinicians and researchers, includes contributions from more than 250 scientists working at leading universities and institutes from across the world.
Caracteristici
Offers an up-to-date review of cancer immunology in animal models and human cancers
Provides a bench to bedside approach to the immunology of cancers, with a focus on clinical aspects
Describes in depth the interactions between cancerous cells and various components of the innate and adaptive immune system
Provides a bench to bedside approach to the immunology of cancers, with a focus on clinical aspects
Describes in depth the interactions between cancerous cells and various components of the innate and adaptive immune system
Recenzii
“This book will provide up to date information about various aspects of tumor immunology. It will be useful to both clinical and experimental oncologists. Accordingly this book should be available through libraries in printed or on-line version for all in need for excellently collected survey of information about tumor immunology.” (Katarina Polakova, Neoplasma, Issue 3, 2015)